{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Chemotherapeutic+Agent", "query": { "intervention": "Chemotherapeutic Agent" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 594, "total_pages": 60, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Chemotherapeutic+Agent&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-10T06:47:20.283Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02171221", "title": "Phase I Study of Oral DFP-11207 in Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "Cancer" ], "interventions": [ { "name": "Oral DFP-11207", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Delta-Fly Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2014-06", "completion_date": "2018-09-13", "has_results": false, "last_update_posted_date": "2019-01-29", "last_synced_at": "2026-09-10T06:47:20.283Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02171221" }, { "nct_id": "NCT00002136", "title": "A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Every 21 Days", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sarcoma, Kaposi", "HIV Infections" ], "interventions": [ { "name": "Tecogalan sodium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-09-10T06:47:20.283Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002136" }, { "nct_id": "NCT01375569", "title": "TRC105 for Liver Cancer That Has Not Responded to Sorafenib", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma", "Hepatocellular Cancer", "Carcinoma, Hepatocellular" ], "interventions": [ { "name": "TRC105", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 11, "start_date": "2011-06-22", "completion_date": "2015-12-01", "has_results": true, "last_update_posted_date": "2017-07-28", "last_synced_at": "2026-09-10T06:47:20.283Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01375569" }, { "nct_id": "NCT06900595", "title": "Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Adrenal Cortical Carcinoma", "Metastatic Adrenal Cortical Carcinoma", "Recurrent Adrenal Cortical Carcinoma", "Stage III Adrenal Cortical Carcinoma AJCC v8", "Stage IV Adrenal Cortical Carcinoma AJCC v8", "Unresectable Adrenal Cortical Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Cemiplimab", "type": "BIOLOGICAL" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 48, "start_date": "2026-02-22", "completion_date": "2029-06-02", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-09-10T06:47:20.283Z", "location_count": 80, "location_summary": "Phoenix, Arizona • La Jolla, California • Madera, California + 60 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Madera", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06900595" }, { "nct_id": "NCT02761694", "title": "Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer", "Solid Tumors" ], "interventions": [ { "name": "Vevorisertib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2016-06-26", "completion_date": "2021-03-10", "has_results": true, "last_update_posted_date": "2023-05-06", "last_synced_at": "2026-09-10T06:47:20.283Z", "location_count": 6, "location_summary": "Las Vegas, Nevada • Oklahoma City, Oklahoma • Charleston, South Carolina + 3 more", "locations": [ { "city": "Las Vegas", "state": "Nevada" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Charleston", "state": "South Carolina" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02761694" }, { "nct_id": "NCT05334329", "title": "Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Lung Non-Small Cell Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Recurrent Lung Non-Small Cell Carcinoma", "Refractory Lung Non-Small Cell Carcinoma", "Stage III Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Antineoplastic Immune Cell", "type": "BIOLOGICAL" }, { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "University of California, Irvine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2022-07-20", "completion_date": "2027-06-14", "has_results": false, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-09-10T06:47:20.283Z", "location_count": 1, "location_summary": "Orange, California", "locations": [ { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05334329" }, { "nct_id": "NCT01096394", "title": "Collection of Tissue Samples From Patients With Stage III or Stage IV Ovarian Epithelial Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Ovarian Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Vanderbilt University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "FEMALE", "summary": "18 Years to 80 Years · Female only" }, "enrollment_count": 20, "start_date": "2009-11", "completion_date": "2015-10", "has_results": false, "last_update_posted_date": "2015-12-10", "last_synced_at": "2026-09-10T06:47:20.283Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01096394" }, { "nct_id": "NCT03972228", "title": "Microdevice for Evaluating Drug Response in Site in Lung Lesions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Lung Tumor", "Lung Cancer" ], "interventions": [ { "name": "Microdevice loaded with 19 chemotherapeutic agents", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Oliver Jonas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2018-10-01", "completion_date": "2021-09-01", "has_results": false, "last_update_posted_date": "2021-09-17", "last_synced_at": "2026-09-10T06:47:20.283Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03972228" }, { "nct_id": "NCT00005931", "title": "SU5416 in Patients With AIDS-Related Kaposi's Sarcoma Who Have Not Responded to Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sarcoma, Kaposi", "HIV Infections" ], "interventions": [ { "name": "SU5416", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SUGEN", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-09-10T06:47:20.283Z", "location_count": 1, "location_summary": "South San Francisco, California", "locations": [ { "city": "South San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005931" }, { "nct_id": "NCT00499616", "title": "Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "topotecan hydrochloride", "type": "DRUG" }, { "name": "Isotretinoin", "type": "DRUG" }, { "name": "Surgery", "type": "PROCEDURE" }, { "name": "Filgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "12 Years", "sex": "ALL", "summary": "Up to 12 Years" }, "enrollment_count": 464, "start_date": "2007-10-08", "completion_date": "2021-06-30", "has_results": true, "last_update_posted_date": "2021-07-06", "last_synced_at": "2026-09-10T06:47:20.283Z", "location_count": 166, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 137 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00499616" } ] }